SCHEMBL21056841

SCHEMBL21056841

COC(=O)c1ccncc1-c1cc(Cl)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 5/20 0.56
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
ACVR1B P36896 2/20 0.46
ACVRL1 P37023 2/20 0.46
ABL1 P00519 1/20 0.46
NUDT1 P36639 1/20 0.45
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
LMNA P02545 1/20 0.43
KCNMA1 Q12791 1/20 0.43
CYP11B2 P19099 2/20 0.43
KDM4C Q9H3R0 1/20 0.42
CSNK2A1 P68400 1/20 0.41
PIM1 P11309 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
NR4A2 P43354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31083379 0.86 ALDH1A1 (0.49) TGFBR1L3MBTL1KDM4EALDH1A1GLA
SCHEMBL31318712 0.85 KCNMA1 (0.54) TGFBR1KDM4EALDH1A1GLAGAA
SCHEMBL21056674 0.83 TGFBR1 (0.51) TGFBR1L3MBTL1KDM4EALDH1A1ACVR1B
SCHEMBL16345011 0.81 TGFBR1 (0.51) TGFBR1L3MBTL1KDM4EALDH1A1GLA
SCHEMBL15240808 0.80 TGFBR1 (0.53) TGFBR1L3MBTL1KDM4EALDH1A1GLA
SCHEMBL4251045 0.80 L3MBTL1 (0.53) TGFBR1L3MBTL1KDM4EALDH1A1GLA
SCHEMBL21056658 0.79 KDM4E (0.47) TGFBR1L3MBTL1KDM4EALDH1A1GLA
SCHEMBL21056631 0.79 SLC6A4 (0.52) TGFBR1L3MBTL1KDM4EALDH1A1GLA
SCHEMBL1462096 0.77 ABL1 (0.61) TGFBR1L3MBTL1KDM4EALDH1A1ABL1
SCHEMBL31511630 0.77 CYP46A1 (0.58) TGFBR1L3MBTL1ALDH1A1ABL1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 US disclosed
CN-112105354-A Fibroblast activation protein inhibitor 普拉西斯生物技术有限责任公司 2020-12-18 CN disclosed
EP-3723753-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2020-10-21 EP disclosed
WO-2019118932-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2019-06-20 WO disclosed
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC 2019-06-20 US disclosed
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FAP, FIBP, FRS2 TGFBR1 1322/4885L3MBTL1 4163/4885KDM4E 3267/4885
US-11780821-B2 Inhibitors of fibroblast activation protein FAP, FIBP, FRS2 TGFBR1 1322/4885L3MBTL1 4163/4885KDM4E 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.